Integrative Analysis Identified MCT4 as an Independent Prognostic Factor for Bladder Cancer
BackgroundBladder cancer is the 10th most common cancer and most common urothelial malignancy worldwide. Prognostic biomarkers for bladder cancer patients are required for individualized treatment. Monocarboxylate transporter 4 (MCT4), encoded by SLC16A3 gene, is a potential biomarker for bladder ca...
Main Authors: | Yang Zhao, Bin Zhao, Wei-Hua Yan, Yan Xia, Zhi-Hui Wang, Guo-Yang Zheng, Wen-Da Wang, Yu-Shi Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-08-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.704857/full |
Similar Items
-
Monocarboxylate Transporter 1 (MCT1) in Liver Pathology
by: Marek Droździk, et al.
Published: (2020-02-01) -
MCT1 and MCT4 Expression During Myocardial Ischemic-Reperfusion Injury in the Isolated Rat Heart
by: Yi Zhu, et al.
Published: (2013-09-01) -
BSG and MCT1 Genetic Variants Influence Survival in Multiple Myeloma Patients
by: Piotr Łacina, et al.
Published: (2018-04-01) -
MCT1 Is a New Prognostic Biomarker and Its Therapeutic Inhibition Boosts Response to Temozolomide in Human Glioblastoma
by: Vera Miranda-Gonçalves, et al.
Published: (2021-07-01) -
MCT4 has a potential to be used as a prognostic biomarker - a systematic review and meta-analysis
by: Arslaan Javaeed, et al.
Published: (2019-07-01)